biostudies-literatureJagadeesh DNational Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient Education and Research FundSeagen IncAnderson Cancer Center CoreTakeda Pharmaceutical Company LtdCutaneous T-Cell LymphomaNational Cancer InstituteHaas Family FoundationNCI NIH HHSMillennium Pharmaceuticals Inc864-873https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526494biostudies-literatureUnknown27(10)<h4>Background</h4>The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV.<h4>Patients and methods</h4>We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients.<h4>Results</h4>Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (The oncologistResponse to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.PMC9526494R21-CA74117K24 CA 86815P30 CA016672SGN35-IST-002SGN35-IST-030K24 CA086815P30 CA008748CA16672-22SGN35-IST-r001Horwitz SDuvic MOnsum MLisano JBartlett NLKim YAdvani RJagadeesh DLittle MFenton KJacobsen ETrepicchio WfalseResponse to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.<h4>Background</h4>The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV.<h4>Patients and methods</h4>We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients.<h4>Results</h4>Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (2022-01-01T00:00:00Z2022 Oct2026-07-14T17:10:49.242Z2025-04-05T17:26:06.51ZS-EPMC95264943594800310.1093/oncolo/oyac137